Phase i study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer

British Journal of Cancer

Volumn 111, Issue 2, 2014, Pages 265-271

  Cohen, S J ^a   Konski, A A ^b   Putnam, S ^a   Ball, D S ^a   Meyer, J E ^a   Yu, J Q ^a   Astsaturov, I ^a   Marlow, C ^a   Dickens, A ^a   Cade, D N ^c   Meropol, N J ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Sirtex Medical Ltd   (Australia)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

capecitabine; phase I; radioembolization

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RADIOPHARMACEUTICAL AGENT; RESIN MICROSPHERE Y 90; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DESQUAMATION; DRUG DOSE ESCALATION; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LD 50; LIVER CELL CARCINOMA; LUNG SHUNTING; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; DEOXYCYTIDINE; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICROSPHERES; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 84904547853     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.344     Document Type: Article

References (34)

1. Ahmadzadehfar H, Sabet A, Muckle M, Wilhelm K, Reichmann K, Biersack HJ, Ezziddin S (2011) 99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. Eur J Nucl Med Mol Imaging 38: 1281-1288.
2. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 26: 5910-5917.
3. Benson 3rd AB, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49: 3122-3130.
4. Bilbao JI, de Martino A, de Luis E, D?́az-Dorronsoro L, Alonso-Burgos A, Mart?́nez de la Cuesta A, Sangro B, Garc?́a de, Jalón JA (2009) Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol 32: 727-736.
5. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6: 56-64.
6. Capecitabine package insert (2014) http://www.accessdata.fda.gov/ drugsatfda-docs/label/2000/20896lbl.pdf (accessed May 14, 2014).
7. Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34: 337-341.
8. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Italian Society of Locoregional Therapies in Oncology (SITILO) (2010) Multicentre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103: 324-331.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
10. DezarnWA, Cessna JT, DeWerd LA, FengW, Gates VL, Halama J, Kennedy AS, Nag S, Sarfaraz M, Sehgal V, Selwyn R, Stabin MG, Thomadsen BR, Williams LE, Salem R. American Association of Physicists in Medicine (2011) Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38: 4824-4845.
11. Diener MK, Combs SE, Büchler MW (2013) Chemoradiotherapy for locally advanced pancreatic cancer. Lancet Oncol 14: 269-270.
12. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, Benito A, Dominguez I, D'Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57: 1078-1087.
13. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. CORRECT Study Group (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303-312.
14. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28: 3687-3694.
15. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL (2006) Metastatic patterns in adenocarcinoma. Cancer 106: 1624-1633.
16. Hofheinz RD,Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13: 579-588.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
18. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74: 1494-1500.
19. Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer (2011) J Vasc Interv Radiol 22: 780-786.
20. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, Liu CS, Salem R, Sangro B, Shuter B, Wang SC (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82: 401-407.
21. Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, Walrand S (2009) Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 36: 1696.
22. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006a) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259.
23. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J (2006b) Incidence and patterns of recurrence after resection for cure of colonic cancer in a well-defined population. Br J Surg 93: 1115-1122.
24. Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC (2011) Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 104: 1067-1070.
25. Mikhail SE, Sun JF, Marshall JL (2010) Safety of capecitabine: a review. Expert Opin Drug Saf 9: 831-841.
26. Okines A, Chau I, Cunningham D (2007) Capecitabine in advanced gastric cancer. Expert Opin Pharmacother 8: 2851-2861.
27. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, Chopitea A, Iñarrairaegui M, Arbizu J, Bilbao JI (2008) Liver disease induced by radioembolization of liver tumors. Cancer (2008) 112: 1538-4156.
28. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35: 1066-1073.
29. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, andleucovorin chemotherapy. J Clin Oncol 25: 1099-1106.
30. Smith DB, Neoptolemos JP (2006) Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 7: 1633-1639.
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216.
32. van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27: 4089-4095.
33. van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88: 78-85.
34. Zheng B, Zheng W, Zhu Y, Lin XY, Xu BH, Chen C (2013) Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis. Chin Med J (Engl) 126: 1178-1182.